15070-17-4Relevant academic research and scientific papers
Carboxyl activation of 3-mercapto-5,6-diphenyl-1,2,4-triazine through N-phenylacetyl-5,6-diphenyl-1,2,4-triazine-3-thione
Rajan
, p. 119 - 126 (2019/01/21)
The carboxyl activation ability of 3-mercapto-5,6-diphenyl-1,2,4-triazine has been established by coverting it into N-phenylacetyl-5,6-diphenyl-1,2,4-triazine-3-thione and this was then subjected to aminolysis and esterification with amines and alcohols respectively and selective aminolysis with aminoalcohols-monitoring chemically and confirmed spectrophotometrically by UV-Visible scannings. It could be proved that 3- mercapto-5,6-diphenyl-1,2,4-triazine is an efficient carboxyl activating group which can be successfully applied in solid phase peptide synthesis.
Efficient and continuous monoacylation with superior selectivity of symmetrical diamines in microreactors
Maurya, Ram Awatar,Hoang, Phan Huy,Kim, Dong-Pyo
scheme or table, p. 65 - 68 (2012/03/26)
Efficient and continuous monoacylation of symmetrical diamines performed in microreactors yielded superior selectivity to that predicted by statistical considerations. It is highly valuable that the kinetically controlled product in high yields was achieved without any special catalyst at ambient temperature.
Nucleoside and DNA adducts from N-nitrosotolazoline
Loeppky, Richard N.,Shi, Jianzheng
, p. 319 - 329 (2008/12/22)
The reaction of N-nitrosotolazoline, the nitrosation product of a representative imidazoline receptor drug tolazoline, with DNA, deoxyguanosine (dG), or deoxyadenosine (dA) produces adducts containing the 2-phenylacetamidoethyl group. The synthesis and ch
Selective Monoacylation of Symmetrical Diamines via Prior Complexation with Boron
Zhang, Zhongxing,Yin, Zhiwei,Meanwell, Nicholas A.,Kadow, John F.,Wang, Tao
, p. 3399 - 3402 (2007/10/03)
(Equation presented) Pretreatment of a symmetrical primary or secondary diamine with 9-BBN prior to the addition of an acyl chloride significantly suppressed undesired diacylation, and the product of monoacylation predominated. The reactive preference is interpreted as the result of a selective deactivation of one nitrogen atom of the diamine by 9-BBN.
Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4- fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors
Choi, Sung-Woon,Elmaleh, David R.,Hanson, Robert N.,Fischman, Alan J.
, p. 3647 - 3656 (2007/10/03)
A series of novel diamine, amine-amide, and piperazinone analogues of N- [2-(bisarylmethoxy)-ethyl]-N'-(phenylpropyl)piperazines, GBR 12909 and 12935, were synthesized and evaluated as inhibitors of presynaptic monoamine neurotransmitter transporters. The primary objective of the study was to determine the structural requirements for selectivity of ligand binding and potency for neurotransmitter reuptake inhibition. In general, the target compounds retained transporter affinity; however, structural variations produced significant effects on reuptake inhibition and transporter selectivity. For example, analogues prepared by replacing the piperazine ring in the GBR structure with an N,N'-dimethylpropyldiamine moiety displayed enhanced selectivity for binding and reuptake inhibition at the norepinephrine (NE) transporter site (e.g. 4 and 5). Congeners in which the amide nitrogen atom was attached to the aralkyl moiety of the GBR molecule showed moderate affinity (K(i) = 51-61 nM) and selectivity for the dopamine transporter (DAT) site. In contrast, introduction of a carbonyl group adjacent to either nitrogen atom of the piperazine ring (e.g. 25 and 27) was not well tolerated. From the compounds prepared, analogue 16 was selected for further evaluation. With this congener, locomotor activity induced by cocaine at a dose of 20 mg/kg was attenuated with an-AD50 (dose attenuating cocaine-induced stimulation by 50%) of 60.0 ± 3.6 mg/kg.
Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses
-
, (2008/06/13)
Novel compounds of the general formula STR1 wherein R1 is lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower alkyl carboxymethyl, aryl carboxymethyl, aryl, or aralkyl; A is a direct bond, lower alkylene, or lower alkenylene; x is 1 or 2, provided that when x is greater than 1, different occurrences of the STR2 group may be the same or different; Ar is heterocyclic, unsubstituted aromatic or aromatic substituted with lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halogen, acetamido, amino, nitro, lower alkylamino, hydroxy, lower hydroxyalkyl or cyano; W is alkylene containing from 1 to about 10 carbon atoms; and B is --NR2 COR3, --NR2 CONR3 R4, --NR2 SO2 R3, --NR2 SO2 NR3 R4, or --NR2 COOR5, wherein R2, R3, R4 and R5 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, alkoxyaryl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R3 and R5 are not hydrogen when B is --NR2 SO2 R3 or --NR2 COOR5, or R3 and R4 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof.
